FS.01 特色科学：管理血脂风险的新方法
北京时间：11月17日 02:30~03:45
LIBerate-OLE - Long-term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72 week Open-Label Extension Trial (LIBerate-OLE)
LIBerate-OLE试验：Lerodalcibep在72周开放标签扩展试验中对1468例心血管疾病极高危和高危患者的长期疗效
LIBerate-HeFH_OLE - Efficacy and Safety of Lerodalcibep, a Third Generation PCSK9 Inhibitor, in 703 Heterozygous Familial Hypercholesterolemia Subjects in the Open Label Extension Trial (LIBerate-HeFH_OLE)
LIBerate-HeFH_OLE试验：第三代PCSK9抑制剂Lerodalcibep在开放标签扩展试验中对703例杂合子家族性高胆固醇血症受试者的疗效和安全性
PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)
PALISADE 研究：评估plzasiran在高风险急性胰腺炎（AP）的遗传或临床定义的家族性乳糜小铁血症综合征（FCS）成人患者中的疗效和安全性的3期研究
YELLOW III - Transcriptomic Signatures and Predictors of Evolocumab Added to Maximum Statin Therapy Based on Intra-Coronary Plaque Characteristics: YELLOW III Study
基于冠状动脉内斑块特征的入最大剂量他汀类药物治疗中加入伊洛尤单抗的转录组特征和预测因素：YELLOW III研究
FS.02 特色科学：健康技术与临床试验的未来
北京时间：11月17日 02:30~03:45
DELIVER - Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical Trials (DELIVER)
在全球临床试验中判断心力衰竭住院情况的自然语言处理：DELIVER研究
MAPS-LLM - Manual versus AI-Assisted Clinical Trial Screening using Large-Language Models (MAPS-LLM)
使用大语言模型进行人工与人工智能辅助临床试验筛选：MAPS-LLM研究
MyoMobile - Personalized App-Based Coaching Improves Physical Activity in Patients With HFpEF Compared to Standard Care – A Randomized Parallel Group Trial (MyoMobile Study)
与标准护理相比，基于应用程序的个性化指导改善HFpEF患者的体力活动：MyoMobile随机平行组试验
mTECH-Rehab - Impact of Technology-Enabled Home-Based Cardiac Rehabilitation on Functional Status and Cardiovascular Health Metrics: The American Heart Association Health Technology Network mTECH-Rehab Randomized Controlled Trial (mTECH-Rehab)
技术支持的家庭心脏康复对功能状态和心血管健康指标的影响：美国心脏协会健康技术网络mTECH-Rehab随机对照试验
FS.03 特色科学：更接近高峰的新型HFpEF治疗方法
北京时间：11月17日 21:00~22:15
Effect of finerenone on a hierarchical composite endpoint analyzed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF
在射血分数轻度降低或保留型心力衰竭患者中使用win统计法分析非奈利酮对分层复合终点的影响：FINEARTS-HF研究的预设分析
Efficacy and safety of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified sex-specific analysis of the FINEARTS-HF trial
非奈利酮治疗射血分数轻度降低或保留型心力衰竭患者的疗效和安全性：FINEARTS-HF研究的预设性别特异性分析
Finerenone and Risk of Hyperkalemia in Patients with Heart failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF)
非奈利酮与射血分数轻度降低或保留型心力衰竭患者发生高钾血症的风险：FINEARTS-HF研究
Effects of Tirzepatide on Cardiorenal End-Organ Damage in Heart Failure and Preserved Ejection Fraction: Insights from the SUMMIT trial
替尔泊肽对射血分数保留型心力衰竭患者心肾终末器官损伤的影响：SUMMIT试验
FS.04 特色科学：聚焦血管治疗结果
北京时间：11月18日 21:00~22:15
Geographical variations of treatment disparities between Black and White patients with peripheral artery disease across the United States
美国黑人和白人外周动脉疾病患者治疗差距的地域差异
Legend 1 - Anatomically Directed Lower Extremity Gene Therapy for Ulcer Healing: A Double Blind, Randomized, Placebo Controlled Study (Legend 1 Trial)
用于溃疡愈合的解剖导向下肢基因疗法：双盲、随机、安慰剂对照Legend 1研究
Bempedoic Acid and Limb Outcomes in Statin-Intolerant Patients with Peripheral Artery Disease: New insights from the CLEAR OUTCOMES Trial
他汀类药物不耐受的外周动脉疾病患者使用贝派地酸的肢体预后：来自CLEAR OUTCOMES试验的新见解
ONCO PE - Rivaroxaban for 18 Months versus 6 Months in Cancer Patients with Low-risk Pulmonary Embolism: ONCO PE Trial
低风险肺栓塞癌症患者服用利伐沙班18个月 vs. 6个月的对比：ONCO PE试验
FS.05 特色科学：淀粉样变性、肥厚性和Danon型心肌病——靶向治疗和特定人群
北京时间：11月18日 22:45~24:00
Danon Disease Phase 1 RP-A501 Results: The First Single-Dose Intravenous Gene Therapy with Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy (Accepted, not confirmed at time of publication)
重组腺相关病毒（AAV9:LAMP2B）治疗单基因心肌病的首个单剂量静脉注射基因疗法：Danon病1期RP-A501研究结果（已接受，发表时尚未确认）
VALOR-HCM - Mavacamten Treatment in Patients with Obstructive HCM Referred for Septal Reduction Therapy: 128-Week Results from VALOR-HCM Trial
Mavacamten治疗转诊为室间隔缩小术的阻塞性HCM患者：VALOR-HCM试验的128周结果
Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes From the ATTRibute-CM Open-Label Extension (OLE) Study
Acoramidis可降低全因死亡率（ACM）和心血管相关住院率（CVH）：ATTRibute-CM开放标签扩展（OLE）研究的初步结果
Impact of vutrisiran on markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial
HELIOS-B试验中vutrisiran对转甲状腺素蛋白淀粉样变性伴心肌病患者疾病进展标志物的影响
SCAN-MP - The prevalence of transthyretin cardiac amyloidosis in older Black and Hispanic individuals with heart failure: The Screening for Cardiac Amyloidosis with Nuclear imaging in Minority Populations Study (SCAN-MP)
转甲状腺素心脏淀粉样变性在老年黑人和西班牙裔心力衰竭患者中的患病率：少数民族人群核成像心脏淀粉样变性筛查研究（SCAN-MP研究）
ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis.
主动脉瓣狭窄和转甲状腺素心脏淀粉样变性双重病理中的ATTR特异性药物治疗
FS.06 特色科学：心血管介入治疗结果的新见解
北京时间：11月19日 02:30~03:45
Semaglutide Improves Cardiovascular Outcomes in Patients with a History of Coronary Artery Bypass Surgery and Overweight or Obesity: The SELECT Trial
司美格鲁肽可改善合并冠状动脉搭桥手术史的超重或肥胖患者的心血管预后：SELECT试验
Five-Year Results from the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE)
Amplatzer Amulet左心耳封堵器随机对照Amulet IDE试验的五年结果
The impact of carbon monoxide to determine the in-hospital prognosis after acute coronary syndrome (ADDICT-ICCU) - (Accepted, not confirmed at time of publication)
一氧化碳对急性冠状动脉综合征后院内预后的影响：ADDICT-ICCU研究（已接受，发表时尚未确认）
Quantitative Assessment of Mitral Annular Calcification Severity Predicts Outcomes in Severe Aortic Stenosis Patients Undergoing Transcatheter Aortic Valve Replacement
二尖瓣环钙化严重程度的定量评估可预测接受经导管主动脉瓣置换术的重度主动脉瓣狭窄患者的预后
FS.07 特色科学：现在是制定护理标准的时候了
北京时间：11月18日 02:30~03:45
